renal cell carcinoma

• 

Effect of antibiotic use on outcomes with systemic therapies in metastatic kidney cancer

By Sharon Kell|2019-10-01T07:51:30+00:001 Oct 2019|Drug treatments|

This study, published in European Urology Oncology this week, investigated [...]

Read More

Comments Off on Effect of antibiotic use on outcomes with systemic therapies in metastatic kidney cancer

• 

ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

By Sharon Kell|2019-09-30T11:18:58+00:0030 Sep 2019|Drug treatments|

Results from the first in human study of the HIF-2α [...]

Read More

Comments Off on ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

• 

ESMO 2019: Results from the TRAXAR study to assess TRC105 plus axitinib for metastatic kidney cancer

By Sharon Kell|2019-09-30T10:55:56+00:0030 Sep 2019|Drug treatments|

Results from the TRAXAR clinical trial to assess TRC105 plus [...]

Read More

Comments Off on ESMO 2019: Results from the TRAXAR study to assess TRC105 plus axitinib for metastatic kidney cancer

• 

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

By Sharon Kell|2019-09-30T10:40:26+00:0030 Sep 2019|Drug treatments|

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab [...]

Read More

Comments Off on ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

• 

ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial

By Sharon Kell|2019-09-30T09:22:24+00:0030 Sep 2019|Drug treatments|

Results from the TITAN-RCC clinical trial to assess tailored immunotherapy [...]

Read More

Comments Off on ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial

• 

ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

By Sharon Kell|2019-09-30T08:45:55+00:0030 Sep 2019|Drug treatments|

Results from the SORCE clinical trial to assess sorfenib as [...]

Read More

Comments Off on ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

• 

ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

By Sharon Kell|2019-09-30T08:35:52+00:0030 Sep 2019|Drug treatments|

Results from the ENTRATA clinical trial to assess telaglenastat in [...]

Read More

Comments Off on ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

• 

Sorafenib versus observation following surgery for metastatic kidney cancer

By Sharon Kell|2019-09-26T07:37:19+00:0026 Sep 2019|Drug treatments|

A potential treatment for a selected group of patients with [...]

Read More

Comments Off on Sorafenib versus observation following surgery for metastatic kidney cancer

• 

‘Revolutionary’ tumour agnostic drug approved for use in Europe

By Sharon Kell|2019-09-25T09:38:33+00:0025 Sep 2019|Drug treatments|

Described by NHS England as "revolutionary" and an "exciting new [...]

Read More

Comments Off on ‘Revolutionary’ tumour agnostic drug approved for use in Europe

• 

European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

By Sharon Kell|2019-09-20T17:17:54+00:0020 Sep 2019|Drug treatments|

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]

Read More

Comments Off on European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer